Home > Publications database > Patient-centered integrated healthcare improves quality of life in Parkinson’s disease patients: a randomized controlled trial > print

001     843730
005     20230217124532.0
024 7 _ |a 10.1007/s00415-018-8761-7
|2 doi
024 7 _ |a 0012-1037
|2 ISSN
024 7 _ |a 0340-5354
|2 ISSN
024 7 _ |a 0939-1517
|2 ISSN
024 7 _ |a 1432-1459
|2 ISSN
024 7 _ |a 1619-800X
|2 ISSN
024 7 _ |a pmid:29392459
|2 pmid
024 7 _ |a WOS:000428928200004
|2 WOS
024 7 _ |a 2128/21355
|2 Handle
024 7 _ |a altmetric:32601461
|2 altmetric
037 _ _ |a FZJ-2018-01282
082 _ _ |a 610
100 1 _ |a Eggers, Carsten
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Patient-centered integrated healthcare improves quality of life in Parkinson’s disease patients: a randomized controlled trial
260 _ _ |a Berlin
|c 2018
|b Springer85301
264 _ 1 |3 online
|2 Crossref
|b Springer Science and Business Media LLC
|c 2018-02-01
264 _ 1 |3 print
|2 Crossref
|b Springer Science and Business Media LLC
|c 2018-04-01
264 _ 1 |3 print
|2 Crossref
|b Springer Science and Business Media LLC
|c 2018-04-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1524560729_25916
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a IntroductionImproving quality of life (QoL) is a key issue when dealing with Parkinson’s disease (PD). Integrative care shows potential to achieve improvements in QoL. Here, we analyzed whether a community-based, open-label, integrated approach improves QoL in PD patients.MethodsPD patients were screened for eligibility and evaluated by a university-based PD specialist, a PD nurse, and a general neurologist at a local practice. Patients were randomly assigned to a control group (CG), receiving standard German neurological treatment including a baseline assessment and follow-up visit at 6 months, or an interventional group (IG) who received an individually tailored therapy plan and additional home visits. Patients and investigators were not blinded for either intervention. Primary outcome analysis compared the differential change of PDQ-39 from baseline to 6-month follow-up between CG and IG. Between-group changes in mood, motor/non-motor functioning, and cognition were secondary outcomes.Results300 patients were included and randomized equally to IG and CG. 132 IG and 125 CG patients had a valid PDQ-39 at follow-up and qualified for the modified ITT analysis. PDQ-39 improved more in IG compared to CG [2.2 points (95% CI − 4.4 to 0.1); p = 0.044]. Likewise, change scores between IG and CG favored IG for UPDRS III (p < 0.001, mean change 3.3, 95% CI − 4.9 to − 1.7) and PD-NMS (p < 0.001, mean change 11.3, 95% CI − 17.1 to − 5.5).ConclusionsData show that an integrated approach, compared to regular PD care, improves QoL as well as motor and nonmotor PD symptoms over 6 months. Future studies need to address the cost–benefit ratio and whether positive effects can be maintained beyond intervention.
536 _ _ |a 572 - (Dys-)function and Plasticity (POF3-572)
|0 G:(DE-HGF)POF3-572
|c POF3-572
|f POF III
|x 0
542 _ _ |i 2018-02-01
|2 Crossref
|u http://www.springer.com/tdm
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Dano, R.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Schill, J.
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Fink, G. R.
|0 P:(DE-Juel1)131720
|b 3
|u fzj
700 1 _ |a Hellmich, M.
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Timmermann, L.
|0 P:(DE-HGF)0
|b 5
773 1 8 |a 10.1007/s00415-018-8761-7
|b Springer Science and Business Media LLC
|d 2018-02-01
|n 4
|p 764-773
|3 journal-article
|2 Crossref
|t Journal of Neurology
|v 265
|y 2018
|x 0340-5354
773 _ _ |a 10.1007/s00415-018-8761-7
|0 PERI:(DE-600)1421299-7
|n 4
|p 764-773
|t Journal of neurology
|v 265
|y 2018
|x 0340-5354
856 4 _ |u https://juser.fz-juelich.de/record/843730/files/10.1007_s00415-018-8761-7.pdf
|y Restricted
856 4 _ |x icon
|u https://juser.fz-juelich.de/record/843730/files/10.1007_s00415-018-8761-7.gif?subformat=icon
|y Restricted
856 4 _ |x icon-1440
|u https://juser.fz-juelich.de/record/843730/files/10.1007_s00415-018-8761-7.jpg?subformat=icon-1440
|y Restricted
856 4 _ |x icon-180
|u https://juser.fz-juelich.de/record/843730/files/10.1007_s00415-018-8761-7.jpg?subformat=icon-180
|y Restricted
856 4 _ |x icon-640
|u https://juser.fz-juelich.de/record/843730/files/10.1007_s00415-018-8761-7.jpg?subformat=icon-640
|y Restricted
856 4 _ |x pdfa
|u https://juser.fz-juelich.de/record/843730/files/10.1007_s00415-018-8761-7.pdf?subformat=pdfa
|y Restricted
856 4 _ |y Published on 2018-02-01. Available in OpenAccess from 2019-02-01.
|u https://juser.fz-juelich.de/record/843730/files/Eggers_2018epub_Post%20print_Journal%20of%20Neurology_Patient-centered%20integrated%20healthcare%20improves%20quality%20of%20life%20in%20Parkinson%27s%20disease%20patients.pdf
856 4 _ |y Published on 2018-02-01. Available in OpenAccess from 2019-02-01.
|x pdfa
|u https://juser.fz-juelich.de/record/843730/files/Eggers_2018epub_Post%20print_Journal%20of%20Neurology_Patient-centered%20integrated%20healthcare%20improves%20quality%20of%20life%20in%20Parkinson%27s%20disease%20patients.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:843730
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)131720
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-572
|2 G:(DE-HGF)POF3-500
|v (Dys-)function and Plasticity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2018
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Embargoed OpenAccess
|0 StatID:(DE-HGF)0530
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts
999 C 5 |a 10.1002/mds.22643
|9 -- missing cx lookup --
|1 P Barone
|p 1641 -
|2 Crossref
|u Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD (2009) The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649
|t Mov Disord
|v 24
|y 2009
999 C 5 |a 10.1002/mds.25844
|9 -- missing cx lookup --
|1 D Berg
|p 454 -
|2 Crossref
|u Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29:454–462
|t Mov Disord
|v 29
|y 2014
999 C 5 |a 10.1212/01.wnl.0000324635.49971.3d
|9 -- missing cx lookup --
|1 NJ Diederich
|p 677 -
|2 Crossref
|u Diederich NJ, Goetz CG (2008) The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology 71:677–684
|t Neurology
|v 71
|y 2008
999 C 5 |a 10.1055/b-002-37755
|1 HC Diener
|y 2012
|2 Crossref
|u Diener HC, Weimar C (2012) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme, Leipzig
|9 -- missing cx lookup --
999 C 5 |a 10.1016/S0140-6736(14)60683-8
|9 -- missing cx lookup --
|1 R Gray
|p 1196 -
|2 Crossref
|u Group PDMC, Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384:1196–1205
|t Lancet
|v 384
|y 2014
999 C 5 |a 10.1002/mds.23638
|9 -- missing cx lookup --
|1 RA Hauser
|p 813 -
|2 Crossref
|u Parkinson Study Group, Hauser RA, Auinger P (2011) Determination of minimal clinically important change in early and advanced Parkinson’s disease. Mov Disord 26:813–818
|t Mov Disord
|v 26
|y 2011
999 C 5 |a 10.1016/j.parkreldis.2015.09.008
|9 -- missing cx lookup --
|1 C Jenkinson
|p 1312 -
|2 Crossref
|u Jenkinson C, Clarke C, Gray R, Hewitson P, Ives N, Morley D, Rick C, Wheatley K, Williams A (2015) Comparing results from long and short form versions of the Parkinson’s disease questionnaire in a longitudinal study. Parkinsonism Relat Disord 21:1312–1316
|t Parkinsonism Relat Disord
|v 21
|y 2015
999 C 5 |a 10.1002/mds.23834
|9 -- missing cx lookup --
|1 P Martinez-Martin
|p 2371 -
|2 Crossref
|u Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, Welsh M, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG, Schrag A (2011) Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Mov Disord 26:2371–2380
|t Mov Disord
|v 26
|y 2011
999 C 5 |a 10.1586/erp.11.106
|9 -- missing cx lookup --
|1 P Martinez-Martin
|p 221 -
|2 Crossref
|u Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ (2012) Quality of life and burden in caregivers for patients with Parkinson’s disease: concepts, assessment and related factors. Expert Rev Pharmacoecon Outcomes Res 12:221–230
|t Expert Rev Pharmacoecon Outcomes Res
|v 12
|y 2012
999 C 5 |a 10.1093/ageing/30.4.299
|9 -- missing cx lookup --
|1 V Peto
|p 299 -
|2 Crossref
|u Peto V, Jenkinson C, Fitzpatrick R (2001) Determining minimally important differences for the PDQ-39 Parkinson’s disease questionnaire. Age Ageing 30:299–302
|t Age Ageing
|v 30
|y 2001
999 C 5 |a 10.1007/BF02260863
|9 -- missing cx lookup --
|1 V Peto
|p 241 -
|2 Crossref
|u Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 4:241–248
|t Qual Life Res
|v 4
|y 1995
999 C 5 |a 10.1111/ene.12950
|9 -- missing cx lookup --
|1 KM Prakash
|p 854 -
|2 Crossref
|u Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK (2016) The impact of non-motor symptoms on the quality of life of Parkinson’s disease patients: a longitudinal study. Eur J Neurol 23:854–860
|t Eur J Neurol
|v 23
|y 2016
999 C 5 |a 10.1159/000479031
|9 -- missing cx lookup --
|1 K Rajiah
|p 131 -
|2 Crossref
|u Rajiah K, Maharajan MK, Yeen SJ, Lew S (2017) Quality of life and caregivers’ burden of Parkinson’s disease. Neuroepidemiology 48:131–137
|t Neuroepidemiology
|v 48
|y 2017
999 C 5 |a 10.1111/ene.12476
|9 -- missing cx lookup --
|1 G Reinoso
|p 457 -
|2 Crossref
|u Reinoso G, Allen JC Jr, Au WL, Seah SH, Tay KY, Tan LC (2015) Clinical evolution of Parkinson’s disease and prognostic factors affecting motor progression: 9-year follow-up study. Eur J Neurol 22:457–463
|t Eur J Neurol
|v 22
|y 2015
999 C 5 |a 10.1177/1054773816634912
|9 -- missing cx lookup --
|1 JY Shin
|p 142 -
|2 Crossref
|u Shin JY, Habermann B (2017) Nursing research in Parkinson’s disease from 2006 to 2015: a systematic review. Clin Nurs Res 24:142–156
|t Clin Nurs Res
|v 24
|y 2017
999 C 5 |a 10.1002/mds.23429
|9 -- missing cx lookup --
|1 CL Tomlinson
|p 2649 -
|2 Crossref
|u Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653
|t Mov Disord
|v 25
|y 2010
999 C 5 |a 10.3233/JPD-150673
|9 -- missing cx lookup --
|1 M Eijk van der
|p 937 -
|2 Crossref
|u van der Eijk M, Bloem BR, Nijhuis FA, Koetsenruijter J, Vrijhoef HJ, Munneke M, Wensing M, Faber MJ (2015) Multidisciplinary collaboration in professional networks for PD. A mixed-method analysis. J Parkinsons Dis 5:937–945
|t J Parkinsons Dis
|v 5
|y 2015
999 C 5 |a 10.1002/mds.25194
|9 -- missing cx lookup --
|1 MA Marck van der
|p 605 -
|2 Crossref
|u van der Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M (2013) Effectiveness of multidisciplinary care for Parkinson’s disease: a randomized, controlled trial. Mov Disord 28:605–611
|t Mov Disord
|v 28
|y 2013
999 C 5 |a 10.1016/S1474-4422(13)70196-0
|9 -- missing cx lookup --
|1 MA Marck van der
|p 947 -
|2 Crossref
|u van der Marck MA, Munneke M, Mulleners W, Hoogerwaard EM, Borm GF, Overeem S, Bloem BR, Group Is (2013) Integrated multidisciplinary care in Parkinson’s disease: a non-randomised, controlled trial (IMPACT). Lancet Neurol 12:947–956
|t Lancet Neurol
|v 12
|y 2013
999 C 5 |a 10.1016/j.euroneuro.2010.08.002
|9 -- missing cx lookup --
|1 S Campenhausen von
|p 180 -
|2 Crossref
|u von Campenhausen S, Winter Y, Rodrigues e Silva A, Sampaio C, Ruzicka E, Barone P, Poewe W, Guekht A, Mateus C, Pfeiffer KP, Berger K, Skoupa J, Botzel K, Geiger-Gritsch S, Siebert U, Balzer-Geldsetzer M, Oertel WH, Dodel R, Reese JP (2011) Costs of illness and care in Parkinson’s disease: an evaluation in six countries. Eur Neuropsychopharmacol 21:180–191
|t Eur Neuropsychopharmacol
|v 21
|y 2011
999 C 5 |a 10.1136/jnnp.74.2.158
|9 -- missing cx lookup --
|1 DT Wade
|p 158 -
|2 Crossref
|u Wade DT, Gage H, Owen C, Trend P, Grossmith C, Kaye J (2003) Multidisciplinary rehabilitation for people with Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 74:158–162
|t J Neurol Neurosurg Psychiatry
|v 74
|y 2003
999 C 5 |a 10.1016/S1474-4422(10)70093-4
|9 -- missing cx lookup --
|1 A Williams
|p 581 -
|2 Crossref
|u Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, Scott R, Ives N, Rick C, Daniels J, Patel S, Wheatley K, Group PSC (2010) Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 9:581–591
|t Lancet Neurol
|v 9
|y 2010
999 C 5 |a 10.1001/jama.2015.120
|9 -- missing cx lookup --
|1 K Kieburtz
|p 584 -
|2 Crossref
|u Writing Group for the NETiPDI, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Perez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM (2015) Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 313:584–593
|t JAMA
|v 313
|y 2015

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21